OTC Acne Treatment Manufacturing in European Union 2026: Industry Statistics & Trends

The over-the-counter (OTC) acne treatment manufacturing sector in the European Union operates at a unique regulatory intersection of the cosmetics and pharmaceutical preparation industries. According to data published by Cosmetics Europe, the total retail sales for the broader European cosmetics and personal care market reached €110 billion in 2025, within which skin care represents the single largest category valued at €32.3 billion. The manufacturing industry continues to pivot toward advanced dermocosmetics and non-antibiotic topical solutions to satisfy tightening European ingredient standards and evolving consumer definitions of dermatological health. Production output is highly robust,

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the OTC Acne Treatment Manufacturing in European Union industry cover?

The OTC acne treatment manufacturing sector in the EU encompasses the formulation, production, and packaging of non-prescription topical skincare products designed to mitigate mild-to-moderate acne vulgaris. Unlike the regulatory framework in the United States, which classifies anti-acne products containing active ingredients like salicylic acid or benzoyl peroxide strictly as OTC drugs, the EU classifies these products based on intent and concentration. Formulations intended for skin purification and beautification operate under cosmetic classifications, while items making explicit therapeutic claims are managed as medicinal products.

• •Encompasses NACE Rev. 2 classifications 20.42 (Manufacture of perfumes and toilet preparations) and 21.20 (Manufacture of pharmaceutical preparations).
• •Covers topical formulations including clarifying cleansers, localized spot gels, exfoliating serums, and specialized non-comedogenic moisturizers.
• •Differentiates strictly between lifestyle skincare items regulated as cosmetics and medicated therapeutic solutions requiring medicinal authorization.

Who operates in the industry and how is it structured?

The supply chain is characterized by a mix of multinational chemical manufacturers, specialized contract manufacturing organizations (CMOs), and global consumer health brands with extensive production facilities inside the EU. Manufacturing nodes are highly concentrated in Western Europe, specifically within Member States that boast advanced pharmaceutical and chemical infrastructure. The manufacturing process relies on sophisticated supply networks providing high-purity raw chemical inputs, stabilizers, and clinical active ingredients.

• •According to industrial statistics from Cosmetics Europe, over 265,000 individuals were directly employed within the cosmetic manufacturing sector in 2025.
• •Primary manufacturing clusters are concentrated within Germany, France, Italy, and Spain, which dominate the region's chemical processing output.
• •Operators heavily utilize dedicated EU-based contract manufacturers to handle complex industrial scaling, formulation stabilization, and compliance batches.

What drives demand in the industry?

Demand for manufactured acne treatments is driven by a structural shift among European consumers from cosmetic concealment to clinical, evidence-based correction. There is a growing public awareness of acne as a chronic dermatological condition requiring long-term care pathways rather than immediate, aggressive intervention. Furthermore, clinical guidelines emphasizing the reduction of systemic antibiotics to combat global antimicrobial resistance have pushed healthcare professionals and consumers toward alternative topical regimens.

• •Driven by a significant clinical pivot across Europe, such as national guidelines restricting the routine prescription of oral antibiotics for mild acne.
• •Supported by robust consumer demand for dermocosmetics, leading to the €32.3 billion valuation of the European skin care market in 2025.
• •Accelerated by rising incidences of adult and hormonal acne, which prolongs the consumer lifecycle well beyond the traditional adolescent demographic.

Who are the notable companies in the industry?

The European manufacturing landscape features intense competition among major public multinationals and localized pharmaceutical enterprises capable of meeting stringent manufacturing standards. Companies compete on the basis of chemical innovation, dermatologist endorsements, and multi-channel distribution viability spanning pharmacies and e-commerce networks. Manufacturers must maintain high capital investment in clinical validation and research and development to differentiate their premium dermocosmetic and medicated portfolios.

• •L'Oréal S.A. operates heavily in the active cosmetics tier, manufacturing dermatologist-endorsed brands like La Roche-Posay and CeraVe within European facilities.
• •Beiersdorf AG manufactures the Eucerin dermocosmetic range out of Germany, maintaining an extensive focus on clinically proven acne-prone skin formulations.
• •Almirall, S.A., a prominent Spain-based pharmaceutical firm, maintains an expansive dermatology manufacturing footprint specializing in targeted skin solutions.
• •Galderma Group AG operates extensive European production networks, advancing therapeutic topical lines alongside its globally recognized Cetaphil portfolio.

What are the recent trends and outlook?

Recent shifts in manufacturing are defined by the development of microbiome-balanced and barrier-repairing topical formulations that minimize skin irritation. Manufacturers are increasingly substituting harsh synthetic chemicals with biotech-derived or clean-certified alternatives to align with regional environmental expectations. The mid-term outlook is highly focused on integrating sustainable, circular-economy packaging requirements while expanding digital-first and telemedicine-aligned corporate supply models.

• •Industrial focus has transitioned heavily toward barrier-safe formulations, utilizing niacinamide, ceramides, and botanical extracts over aggressive acids.
• •Export demand remains a critical growth vector, leveraging the premium global reputation of EU manufacturing which yielded €29.8 billion in exports in 2025.
• •Supply chains are adjusting to accommodate e-commerce and subscription models, requiring flexible packaging and specialized small-batch manufacturing.

How is the industry regulated?

Compliance within the European Union is governed by some of the world's most stringent legal frameworks, guaranteeing safety, accurate labeling, and environmental responsibility. Products classified as cosmetics must adhere strictly to Regulation (EC) No 1223/2009, which enforces strict ingredient prohibitions, safety assessments, and a absolute ban on animal testing. Formulations making explicit therapeutic claims fall instead under the jurisdiction of the European Medicines Agency (EMA) and must comply with Good Manufacturing Practices (GMP).

• •Cosmetic formulations are governed by Regulation (EC) No 1223/2009, which requires a detailed Cosmetic Product Safety Report (CPSR) prior to retail.
• •Manufacturing plants must strictly adhere to ISO 22716 standards for Cosmetic Good Manufacturing Practices (GMP) to ensure production safety consistency.
• •Medicated topicals, such as newly authorized substances like clascoterone (Winlevi) approved in 2025, require rigorous EMA centralized marketing authorization.
• •Compliance mandates require full supply chain visibility to ensure compliance with the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation.

Government, statistical and trade sources used for this Claight analysis.

• Cosmetics Europe Market Performance Report 2025 ·
• European Medicines Agency (EMA) Medicine Overview 2025 ·
• Eurostat Structural Business Statistics Database 2025 ·
• European Commission Regulation (EC) No 1223/2009 on Cosmetic Products